AACR Tumor Immunology and Immunotherapy 2019
November 27, 2019
Last week, the ACIR team attended the AACR Tumor Immunology and Immunotherapy conference in Boston, MA. This week’s extensive special feature is made possible thanks to the support of Takeda. It covers select sessions from the conference organized as follow: Exhaustion and Therapy ResistanceCell TherapyMyeloid Compartment in the TMEVaccines and AntigensMicrobiome Exhaustion and Therapy Resistance...
Rotavirus vaccine and anti-CTLA-4: a dynamic duo
November 20, 2019
Aiming to increase the number of patients, particularly pediatric patients, who respond to immune checkpoint blockade (ICB), Shekarian et al. explored whether existing anti-infectious disease vaccines could be used to increase the immunogenicity of tumors and overcome resistance to ICB. The results, recently published in Science Translational Medicine, suggest that the clinical-grade rotavirus...
Combination ICB is greater than the sum of its parts
November 13, 2019
Anti-PD-1 and anti-CTLA-4 work through distinct mechanisms, and evidence from preclinical and early clinical trials has shown that these two checkpoint blockade therapies can be even more powerful when used in combination. To determine exactly how this combination works, Wei et al. set out to uncover whether the effects of combining anti-CTLA-4 and...
A little help from CD4+ T cells enables immunotherapy success
November 6, 2019
Aiming to understand the requirements for successful immunotherapy outcome, Alspach et al. explored the role of CD4+ T cells in antitumor response and found that expression of MHC-II neoantigens in the tumor, activation of CD4+ T cells, and CD4+ T cell help for CD8+ T cell priming and maturation were critical for response...